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Altered metabolism can occur when the metabolic 
hormones, leptin and thyroid hormone become unresponsive to 
blood nutrient levels. Leptin is secreted from adipose 
tissue in response to food intake, resulting in appetite 
suppression and increased metabolism. Thyroid hormone (T3) 
regulates genes involved in energy utilization, lipolysis, 
and lipogenesis, and stimulates metabolism.
Obese mice (ob/ob) are leptin deficient and are widely 
used to study the effects of leptin on metabolism. In this 
study, twenty nine week old C57BL/6J ob/ob mice were 
injected for seven days with vehicle, leptin, iopanoic acid 
(IOP, to reduce T3 concentration) , or a combination of 
leptin and IOP (n=5/group). Mice were analyzed for changes 
in mass-specific oxygen consumption, respiratory quotient, 
body weight, and food intake over the treatment period. 
Hepatic lipid content and lipid droplet size, and adipocyte 
area were determined post mortem.
Leptin decreased liver lipid content and lipid droplet 
size, and increased omental adipocyte area, suggesting 
leptin has the ability to reduce excess lipid storage in 
the liver by shuttling lipid to adipocytes. The IOP treated 
mice were not different from the vehicle treated mice with 
regards to adipocyte area and liver lipid content. The 
leptin/IOP treated mice had increased hepatic lipid content 
and lipid droplet size, and the smallest adipocytes. This 
suggests that reduced thyroid hormone is the limiting 
factor regarding metabolizing and exportation of hepatic 
lipids, and suggests a possible link between thyroid 
hormone and leptin in regulating lipid metabolism.
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CHAPTER ONE
LITERATURE REVIEW OF ENERGY HOMEOSTASIS 
Background
Obesity has become an increasingly serious problem in 
the Western hemisphere and can cause serious health 
problems, primarily cardiovascular disease. The cellular 
mechanisms underlying the development of obesity have been 
obscure, but in 1994 the discovery of the hormone leptin 
changed the way obesity and diabetes research was conducted 
and provided a new way to approach the study of the 
metabolic syndrome (Zhang et al. 1994). Obesity may result 
from improper eating, leading to an increase in fat stores, 
which leads to an altered metabolism. Altered metabolism 
occurs when cells that produce hormones involved in 
nutrient trafficking become unresponsive to blood nutrient 
levels, resulting in uncontrolled appetite and improper 
storage of nutrients. It is important to study how the key 
metabolic hormones, insulin, leptin, and thyroid hormone, 
alter metabolic pathways and lipid and glucose trafficking 
in order to find possible therapies for treatment of 
obesity and its complications.
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Energy Homeostasis
Energy homeostasis is the regulation of body weight by 
the brain and peripheral tissues to maintain a stable, 
internal environment in the presence of a dynamic external 
environment. This is dependent upon the balance between 
food intake as well as anabolic and catabolic pathways, or 
the building up and breaking down of molecules, 
respectively. Particularly, signals from peripheral tissues 
are transmitted to the brain when a change in body energy 
reserves are "sensed" due to alterations in energy 
expenditure, nutrient partitioning, and energy intake.
Maintenance of energy homeostasis is a complex process 
that is mediated by multiple endocrine and neurocrine 
feedback loops to and from the central nervous system (CNS) 
and involves cross-talk among many tissues, including the 
brain, liver, skeletal muscle, stomach, pancreas, and 
adipose tissue. The sympathetic nervous system (SNS) of the 
CNS regulates whole body metabolism by its actions on 
neurons of the hypothalamus. These neurons secrete 
neurohormones (releasing hormones) that trigger the 
secretion of hormones from the anterior pituitary gland. In 
turn, the pituitary gland links the nervous and endocrine 
systems. The anterior pituitary hormones bind to specific 
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cellular receptors, eliciting their respective responses, 
which can then feedback to the SNS to turn down their 
secretion.
The SNS is important in regulating appetite. Feeding 
is regulated by signals from the arcuate nucleus located 
within the hypothalamus (Elmquist et al. 1998b). 
Neuropeptide Y (NPY) and agouti-related peptide (AgRP) 
stimulate appetite while proopiomelanocortin (POMC) and 
melanocortin stimulating hormone (oc-MSH) induce a decrease 
in appetite (figure 1). NPY is also known to inhibit 
thermogenesis (Billington et al. 1991; Dryden and Williams 
1996). Decreased thermogenesis reduces oxygen consumption, 
allowing nutrients (glucose and lipids) to be stored 
instead of being utilized to support oxygen consumption. A 
rise in stored nutrients reduces appetite stimulation so 
that overeating does not occur.
Neurons of the hypothalamus are stimulated by the 
hormones ghrelin, insulin, and leptin, which in turn are 
regulated by circulating glucose and free fatty acid levels 
and intracellular glycogen and triacylglycerol (TG) stores 
(Houseknecht 1998). While ghrelin stimulates appetite 
through AgRP and NPY, insulin and leptin cause appetite 
inhibition through inhibition of the same neurons and
3
Figure 1. Hormonal Control of Feeding Regulation. 
Feeding regulation is controlled by hormones 
released from the stomach, pancreas, and adipose 
tissue. When nutrients are available, insulin and 
leptin are secreted from the pancreas and 
adipocytes, respectively, to inhibit AgRP and NPY 
while simultaneously stimulating POMC and aMSH. This 
inhibition and stimulation leads to an inhibition of 
feeding on the PVN. When nutrients are absent, 
ghrelin is released from the stomach/duodenum and 
stimulates AgRP and NPY, which leads to a 
stimulation of feeding on the PVN. AgRP= agouti- 
related peptide; NPY= Neuropeptide Y; POMC= 
proopiomelanocortin; aMSH= melanocortin stimulating 
hormone; PVN= paraventricular nucleus
stimulation of POMC and a-MSH (figure 1). (Due to the focus 
of this thesis, ghrelin will not be discussed. For further 
information see review by Lazarczyk et al. 2003.) Insulin 
is secreted from pancreatic p cells when plasma glucose 
levels rise after a meal and through its actions on the 
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hypothalamus, it stimulates glucose and free fatty acid 
uptake into peripheral tissues. Glucose uptake in skeletal 
muscle and adipose tissue is directly dependent on insulin. 
However, in the liver, insulin indirectly facilitates 
diffusion of glucose into hepatocytes, but some glucose can 
still diffuse into hepatocytes even in the absence of 
insulin. When glucose enters hepatocytes, it can 
immediately enter glycolysis, increasing the production of 
cellular energy, or be converted to its storage form, 
glycogen. If insulin is oversecreted due to chronic 
elevated plasma glucose (e.g. from overeating), its signal 
on cells will be ignored, referred to as accommodation or 
insulin resistance. Insulin resistance will decrease 
glucose uptake and lead to hyperglycemia (Houseknecht et 
al. 1998a).
While insulin elicits its responses over the short 
term (hours), leptin can elicit the same responses over the 
longer term (days). Leptin is a hormone of the cytokine 
family and is secreted by adipose cells in response to 
energy intake (Tartaglia et al. 1995). In addition to 
insulin-like effects, leptin can also control feeding 
behavior (Houseknecht et al. 1998b). For instance, when 
adipocytes increase in size due to a post-prandial (after 
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meal) increase in stored nutrients, leptin is secreted from 
adipocytes to inhibit appetite. Lack of appetite 
inhibition, i.e. low leptin levels, can lead to overeating. 
There is an importance in understanding the changes in 
glucose and lipid metabolism in response to nutritional 
status in obese individuals, who may be leptin deficient 
(Houseknecht et al. 1998b).
Leptin gene expression is regulated by the size of 
adipocytes as well as insulin and glucocorticoids (Caro et 
al. 1996). There is a positive correlation between adipose 
tissue mass and fat cell size to the quantity of leptin 
secreted (Houseknecht et al. 1998a; Caro et al. 1996). 
Adipose cells sense excess fat storage and stimulate the 
release of leptin, which then leads to an increase in total 
body energy expenditure, decreased food intake, and 
normalization of body weight in obese mice within 2 weeks 
or less (Halaas et al. 1995; Maffei et al. 1995). Leptin 
acts either directly, binding to receptors on its target 
cells (e.g. liver), or indirectly by binding to leptin 
receptors in the hypothalamus because leptin is able to 
penetrate the blood-brain barrier. Leptin that targets the 
hypothalamus then stimulates the release of neurohormones, 
such as thyroid stimulating hormone and growth hormone
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(Houseknecht et al. 1998b), from the pituitary to induce 
their respective cellular responses (Elmquist et al. 1998b; 
Houseknecht et al. 1998b; Fehn et al. 1999). Pelleymounter 
et al. (1995) showed that leptin administration to leptin 
deficient obese mice (ob/obr refer to section "the ob/ob 
mouse model", p. 23) stimulated an increase in basal 
metabolic rate and thermogenesis, leading to a reduction in 
body weight. The administration of leptin to ob/ob mice 
decreases food intake and restores neuroendocrine functions 
that are lost as a result of leptin deficiency. These 
include infertility derived from decreased hypothalamic 
leutinizing hormone secretion in ob/ob mice, among other 
reproductive abnormalities (Halaas et al. 1995;
Pelleymounter et al. 1995; Campfield et al. 1995; Chehab et 
al. 1996). Furthermore, Fehn et al. (1999) showed that 
leptin administration also increased thyroid hormone 
concentrations in ob/ob mice due to enhanced thyroid 
follicular cell activity leading to enlarged colloids. Reno 
and Fehn (2007) also showed that SNS-ablated ob/ob mice and 
hyperthyroid ob/ob mice were rescued from hepatic steatosis 
(fatty liver) with administration of leptin. This result 
shows that leptin can elicit physiological responses 
independently of the SNS and in the presence of excess 
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thyroid hormone, supporting the importance of leptin in 
maintaining energy homeostasis. However, the extent of 
these responses has only been studied at a histological 
level and needs to be examined further by molecular 
analyses. Additionally, when the SNS is activated by 
leptin, lipolysis in white adipose tissue is stimulated 
(Siegrist-Kaiser et al. 1997; Fruhbeck et al. 1997), 
releasing free fatty acids for use in metabolism.
The pathologies 'associated with obesity and diabetes, 
among others, are often linked with either a complete 
absence of leptin or the brain's inability to respond to 
leptin (i.e. leptin resistance) because without leptin's 
actions, there is improper storage and release of glucose 
and fatty acids, primarily in adipocytes and hepatocytes 
(Halaas et al. 1995; Pelleymounter et al. 1995; Campfield 
et al. 1995; Chehab et al. 1996).
Even though leptin can affect energy metabolism 
through the hypothalamus (i.e. CNS) and/or through 
receptors located directly on peripheral tissues (Elmquist 
et al. 1998; Houseknecht et al. 1998b; Fehn et al. 1999; 
Fei et al. 1997; Elmquist et al. 1998a; Mercer et al. 1996; 
Schwartz et al. 1996), research has primarily focused on 
its CNS effects (Tartaglia et al. 1995; Caro et al. 1996;
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Halaas et al. 1995; Pelleymounter et al. 1995). Recently, 
this focus has shifted to trying to understand the 
mechanisms of direct leptin stimulation of peripheral 
target cells. The cellular responses to leptin are 
dependent on the concentrations of circulating glucose, 
free fatty acids, and other hormones such as insulin 
(Houseknecht et al. 1998a; Stephens and Caro 1998). The 
liver is one of the main regulators of macronutrient 
metabolism, controlling serum free fatty acid and glucose 
levels in response to serum leptin concentrations. Serum 
glucose levels affect the activity of key enzymes involved 
in metabolic processes, such as glycolysis and (5-oxidation. 
After sufficient quantities of glucose are taken up into 
tissues (primarily liver) to meet energy requirements, 
glucose is converted into its storage form, glycogen, in 
order to prevent excess secretion of glucose back into the 
blood. During the post-prandial period, a rise in serum 
glucose levels causes pancreatic B cells to secrete insulin 
(figure 2), which activates glycogen synthetase and leads 
to an increase in hepatic glycogen storage. In a fasting 
state, pancreatic a cells respond to the serum glucose 
deficiency and secrete glucagon, which together with 
epinephrine activates phosphorylase in the liver to convert
9
Glucose Regulation By Pancreatic Cells
R. Felm
Figure 2. Glucose Regulation by Pancreatic a and 0 
Cells. Increases in plasma glucose are sensed by 
pancreatic 0 cells, which secrete insulin, signaling the 
liver to store glucose. High levels of plasma glucose 
also inhibit glucagon secretion from pancreatic ot cells. 
Plasma glucose deficiency is sensed by pancreatic, ex 
cells, leading to glucagon secretion and the release of 
glucose from the liver. Pancreatic ot cells also stimulate 
insulin secretion from pancreatic 0 cells, preventing 
hyperglycemia due to hepatic glucose release.
glycogen into glucose. This glucose is released from the 
liver into the blood to be used for cellular energy by 
peripheral tissues via glycolysis. Since glycolysis 
produces acetyl-CoA, which is required to produce fatty 
acids, the concentration of glucose or glycogen present in 
the liver can indirectly control the rate of fatty acid 
formation, which can affect the amount of fatty acid stored 
as TG. For example, if hepatic glucose concentrations 
increase to support an increase in glycolysis, then more 
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fatty acids can be built, causing the excess fatty acids to 
be stored as TG (Gibbons et al. 2000).
In addition to stimulating the conversion of glycogen 
to glucose, glucagon can also stimulate lipolysis in 
adipose tissues, which decreases the size of adipocytes and 
provides free fatty acids to potentially be utilized in 
hepatic glucogenesis. Furthermore, glucagon stimulates the 
activity of enzymes that lead to the [3-oxidation of fatty 
acids. Abnormalities associated with increased serum 
glucagon can cause' the release of excess glucose and fatty 
acids into the blood, which then leads to altered insulin 
sensitivity. If insulin sensitivity is decreased, then the 
storage and release of glucose will be decreased and that 
of fatty acids increased. This reduced glucose uptake into 
adipose tissue and skeletal muscle due to insulin 
resistance can lead to hyperglycemia, hyperlipidemia, 
and/or excess TG storage in the liver. The overproduction 
of both hepatic glucose and fatty acids can occur as a 
result of chronic overeating. This leads to a mistaken 
sensation of low plasma glucose and fatty acids by the 
pancreas due to altered glucose and lipid trafficking. 
Overproduction of glucose and fatty acids leads to 
hypersecretion of these molecules into the blood. This 
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causes a rise in serum glucose and free fatty acid levels 
and stimulates the release of more insulin from pancreatic 
3 cells, which will exacerbate peripheral insulin 
resistance (McGarry 1992), a key factor in the development 
of obesity and type II diabetes. Once insulin resistance 
occurs, there is a continual sensation of excess 
macronutrients in the blood, and this condition will cause 
excessive storage of the glucose and fatty acids, not only 
in adipocytes, but in hepatocytes as well. Therefore, the 
control of glucose production and release is a key factor 
in regulating overall lipid metabolism.
Lipids
Obesity and diabetes are associated with dysregulation 
of hepatic lipid synthesis. Acetyl-CoA carboxylase (ACC) 
and fatty acid synthase (FAS) are hepatic lipogenic enzymes 
whose gene transcription is regulated by cellular nutrient 
levels (Towle et al. 1997). Fatty acids are synthesized 
when cellular energy is .in demand and are either utilized 
immediately or combined with glycerol to form TG to be 
stored as neutral lipids. Neutral lipids, including 
triacylglycerols (TG), steryl esters (SE), and wax esters 
(WE), are lipids which are unable to penetrate 
phospholipids bilayers (Athenstaedt and Daum 2006) .
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Sterols, free fatty acids, and diacylglycerols (DAG) are 
stored intracellularly after conversion to TGs and SEs. TGs 
are the major form of lipid storage within tissues, and the 
fatty acids stored as TG may be oxidized by [3-oxidation to 
produce cellular energy. Therefore, regulation of the 
release of fatty acids from their neutral lipid storage 
form may be key in regulating metabolic expenditure.
Neutral lipids are stored in intracellular 
compartments called lipid droplets (LD). The lipid droplet 
consists of a phospholipid monolayer, with just a few 
embedded proteins that control the extraction and 
hydrolysis of lipids from LDs, and a hydrophobic core 
containing the neutral lipids (Athenstaedt and Daum 2006). 
Lipases and hydrolases regulate the release of neutral 
lipids from the cores of LDs. These neutral lipids can then 
be broken down to fatty acids that can be utilized by the 
cell. The free fatty acids and DAG are oxidized primarily 
for energy.
The exact mechanisms of how LDs form are still under 
investigation. Van Meer (2001), Ostemeyer et al. (2001)', 
and Murphy et al. (1999) propose that as neutral lipids are 
being synthesized between the two leaflets of the 
endoplasmic reticulum (ER), they accumulate due to their 
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inability to pass through the ER membrane. Once the neutral 
lipids reach a certain size, they bud off one leaflet of 
the ER and enter the cytosol as a lipid droplet. Once lipid 
droplets are formed, they can increase in size by de novo 
synthesis of neutral lipid using enzymes embedded in the 
phospholipid monolayer and/or within the core of the LD 
(Athenstaedt and Daum 2006). The core contains the 
necessary components necessary to make the precursors that 
form TG. Pathologies associated with obesity and diabetes 
arise in part because of problems accessing neutral lipids 
in the LDs to extract the fatty acids. This problem results 
in the accumulation of excess lipids and larger LDs within 
the liver and adipose tissue (Greenberg et al. 2006). 
Adipose Tissue and Triacylglycerol Hydrolysis
Adipose tissue is not only a major storage depot for 
excess fat, but more recently it has been found to be an 
endocrine organ involved in the regulation of whole-body 
metabolism (Mohamed-Ali et al. 1998). While leptin is 
secreted from adipose tissue, other hormones such as 
thyroid hormone may stimulate adipose tissue to further 
regulate metabolism. Leptin and thyroid hormone regulate 
the activity of adipose lipolytic enzymes and thus .control 
the hydrolysis of TG within adipocytes. Hormone sensitive 
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lipase (HSL) is the best-studied adipose lipase and works 
to induce lipolysis via a cyclic-AMP (cAMP)-meditated 
phosphorylation cascade that translocates HSL to the 
surface of LDs where it can then access and hydrolize the 
newly released TG into glycerol and fatty acids. In 
addition to HSL, other lipases may be activated by other 
cell signals that regulate the same process. For instance, 
deletion of the murine HSL gene only decreased half of the 
TG lipase activity in adipocytes, suggesting that at least 
one other enzyme also facilitates this process (Wang et al. 
2001; Osuga et al. 2000). Triacylglycerol hydrolase (TGH) 
is also found in adipose tissue (Dolinsky et al. 2001). W. 
Gao and R. Lehner showed that reducing murine TGH 
expression reduced adipocyte free fatty acid release and 
caused a 40% decrease in plasma free fatty acids 
(Athenstaedt and Daum 2006). More recently, adipose 
triglyceride lipase (ATGL) was discovered by Zimmerman et 
al. (2004), and they demonstrated that ATGL is responsible 
for 70% of TG lipase activity in adipose tissue, an 
apparent conflict with previous reports on HSL and TGH 
activity. This result suggests that the activity of HSL and 
TGH may have been overestimated and that ATGL might be just 
as important for lipolysis. More work is needed to examine 
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the possibility that the activity of any of the lipases is 
affected by the absence or presence of the other ones.
The hydrolysis of TG occurs in response to a signal 
released from the SNS that fatty acids are needed for 
metabolism. These fatty acids are secreted into the 
bloodstream for circulation to their target tissues, 
primarily skeletal muscle and liver. If they are not needed 
in these tissues or cannot be taken up due to insulin 
insensitivity, they may remain in circulation for longer 
periods of time. The misregulation of the release and 
hydrolysis of TG is a critical factor in the development of 
insulin resistance, hyperinsulinemia, hyperglycemia, and 
dyslipidemia because glucose uptake into muscle and liver 
is also altered when there is a chronic increase in 
circulating free fatty acids (Boden and Shulman 2002; Boden 
2003). Thus, the genes and proteins that control the 
activity of HSL, TGH, and ATGL are possible links to the 
observed defects in the obese syndrome that leads to 
insulin resistance.
Thyroid Hormone
The thyroid gland is an important organ that is 
involved in various physiological processes. A negative 
feedback loop that involves the hypothalamus, pituitary, 
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and thyroid gland controls the synthesis and secretion of 
thyroid hormones (Shupnik et al. 1989). Thyroid hormones 
are derived from the amino acid tyrosine. The two main 
types of thyroid hormones are 3,5,3',5'-tetraiodo-L- 
thyronine (T4) and 3,5,3'-triido-L-thyronine (T3) , which 
differ by the number of iodide ions they contain. Iodide is 
taken up by the follicular cells of the thyroid gland via a 
Na+-I” co-transport system driven by the plasma membrane Na+ 
gradient and becomes oxidized to an active form. This 
reactive iodide reacts with specific tyrosine residues 
within thyroglobulin (Tg, protein produced by thyroid 
gland) via oxidative coupling to form either 3- 
monoiodotyrosine (MIT) or 3, 5-diiodotyrosine (DIT). If two 
DIT moieties are joined together, then T4 is produced. If 
one MIT and one DIT moiety are joined, then T3 is produced. 
The signal to produce thyroid hormones occurs when the 
pituitary gland releases thyroid stimulating hormone (TSH), 
which stimulates intracellular cAMP production in the 
follicular cells of the thyroid gland, leading to the 
production of T4 and T3. Tg contains MIT, DIT, T3, and T4 and 
is stored as a colloid droplet within the follicular lumen 
for immediate release when needed. To release T4 and T3, Tg 
undergoes endocytosis from the lumen at the apical surface 
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of the follicular cell and is digested inside the cell to 
release the hormones, which then diffuse into the blood 
vessels for circulation to their target tissues (Taurog 
1996).
Total serum T4 is 40-fold higher than total serum T3; 
however, T4 is not as widely used by target tissues as T3, 
but both T4 and T3 have been shown to produce physiological 
responses. Most of the serum T3 and T4 are bound to 
thyroxine binding globulin, albumin, or thyroid binding 
prealbumin when in an inactive form. Thyroid hormones must 
be released from the protein carriers to enter target cells 
to elicit biological responses. T3 is involved in numerous 
physiological processes and is in higher abundance in the 
free form than T4 (Yen 2001) . However, even though free T3 
is more abundant than free T4, most of the T3 effects are 
exerted when T4 is converted to T3 locally at the tissues 
(Yen 2001) . At the liver and kidney, T4 is converted to T3 
by type I deiodinase, and this accounts for most of the T4 
turnover observed in circulation (Braverman et al. 1970; 
Kohrle 2000). Additionally, T4 is converted to T3 
intracellularly by type II deiodinase in the brain, 
pituitary, and brown adipose tissue.
18
Both thyroid hormones activate transcription of 
specific genes by binding to a member of the thyroid 
receptor (TR) family located in the nucleus of cells of 
various organs. When T3 is bound to TR, gene transcription 
is activated through thyroid response elements (TRE), which 
are sometimes pre-bound to TRs, located on the promoter 
regions of target genes. When T3 is not bound to TRs, there 
is repression of gene transcription (Zhang and Lazar 2000). 
Thyroid Hormone and Adipose Tissue
Adipocyte differentiation has been shown to be induced 
by T3. Grimaldi et al. (1982) demonstrated that 
preadipocytes from young rats, as well as cells from 
preadipocyte cell lines, were induced to become white 
adipose tissue when treated with T3, as shown through 
stimulated intracellular lipid accumulation, transcription 
of key lipogenic enzymes, and adipocyte cell proliferation. 
The lipogenic enzymes that are induced include ATP-citrate 
lyase, malic enzyme, and fatty acid synthase, all of which 
can lead to the synthesis of fatty acids (Blennemann et al. 
1995; Gharbi-Chihi et al. 1991).
Thyroid hormones indirectly regulate lipolysis in 
adipocytes by enhancing the binding of catecholamines to 0- 
adrenergic receptors on adipocytes; thyroid hormones 
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increase p-adrenergic receptor density and decrease 
phosphodiesterase activity (Engfeldt et al. 1982; 
Wahrenberg et al. 1986). p-adrenergic signaling activates 
adenylate cyclase and mediates a signal transduction 
cascade via the second messenger cAMP, leading to the 
activation of lipases that catalyze the breakdown of 
triacylglycerol (via HSL) into fatty acids and glycerol. 
Therefore, lipid metabolism can be altered depending upon 
thyroid status.
The quantity of circulating thyroid hormones may be 
altered due to defects in the feedback loop that controls 
thyroid hormone secretion. Hyperthyroidism and 
hypothyroidism occur when there is over secretion and under 
secretion of thyroid hormones from the thyroid gland, 
respectively. During a state of hyperthyroidism, 
hyperplasia (increase in cell number) and an increase in 
lipolysis occurs in adipocytes (Levacher et al. 1984). 
Hypothyroidism, on the other hand, results in hypertrophy 
(increase in cell size) and decreased lipolysis in 
adipocytes, resulting in less available free fatty acids 
for metabolic use. Furthermore, hypothyroidism is 
associated with low metabolic rate, low body temperature, 
slow heart rate, and weight gain (Hadley 2000). Therefore,
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during hypothyroidism, adipocytes are expected to increase 
in cell size when compared to a euthyroid state (normal 
thyroid function) because the cells are saving energy due 
to the effects of low T3.
Thyroid hormones regulate genes involved in energy 
utilization, lipolysis, and lipogenesis. However, these 
processes do not all occur in the same time frame. In a 
study of chronic T3 injections in adult rats (Oppenheimer et 
al. 1991), total oxygen consumption, which is a measurement 
of metabolic rate, reached its peak in only 4 days of 
treatment, and by the sixth day, the amount of total body 
fat storage dropped by half. However, caloric intake did 
not reach its peak until day 8, after continually 
increasing during the previous treatment days. The animals 
probably still lost body fat despite increased caloric 
intake because metabolic rates were increased as well, and 
the calories were needed to maintain energy levels that 
were being depleted due to increased lipolysis. 
Furthermore, transcription of genes needed for 
thermogenesis, lipolysis, and lipogenesis were upregulated 
by thyroid hormone before they were even needed. This 
suggests that thyroid hormone-stimulated lipolysis is not 
directly linked to thyroid hormone-stimulated energy 
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utilization because genes needed for lipolysis are 
upregulated as a default mechanism, and this occurs before 
energy is required.
Thyroid Hormone and Liver
Thyroid hormones can also have multiple effects on 
the liver. For instance, malic enzyme is a lipogenic enzyme 
found in the liver, as well as other tissues. In a study by 
Strait et al. (1989), the transcription of hepatic malic 
enzyme showed biphasic regulation, as expression increased 
at 4 hours and again at 24 hours in response to T3 
treatment. This suggests that while T3 has initial direct 
effects, secondary effects caused by genes initially 
upregulated by T3 also elicit the same type of response as 
T3 on its target tissues. The specific effects of T3 on its 
target tissues can be dependent upon carbohydrate intake, 
insulin, and cAMP (Oppenheimer et al. 1987, 1991). Because 
of these variables, there needs to be consistency in 
experimental design, using either fasting or non-fasting 
animals, because the presence or absence of food can alter 
the activity of T3. For instance, in fasted animals, T3 has 
only minimal effects on the induction of malic enzyme, 
whereas animals fed a high carbohydrate diet show the 
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highest levels of T3-stimulated. malic enzyme lipogenesis 
(Oppenheimer et al. 1987, 1991).
Thyroid hormone regulates the expression of about 8% 
of hepatic genes in vivo (Oppenheimer et al. 1987). Feng et 
al. (2000) used a cDNA microarray to identify the hepatic 
genes that are regulated by thyroid hormone. In hypothyroid 
mice treated with T3, microarray analysis revealed that 14 
genes were up-regulated and 41 were down-regulated. These 
included genes involved in various cellular processes, 
including increasing glycogenolysis, gluconeogenesis, 
lipogenesis, cAMP activity, [32-Adrenergic receptor 
activity, proliferation, and apoptosis. It also included 
genes that decreased insulin action, immunogenecity, and 
protein glycosylation.
The ob/ob Mouse Model
With failed attempts to treat obese human patients 
with leptin injections (Houseknecht et al. 1998a), there 
has been an increasing need to understand the mechanisms 
involved in lipid trafficking in order to determine 
appropriate routes for therapy. Since leptin reduces 
appetite and lowers fat mass in mice, it is inconclusive as 
to why treatment with leptin does not work as a therapeutic 
agent in humans. Abnormalities in other hormone 
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concentrations that occur in obesity may hinder the action 
of leptin. Leptin may possibly interact with these other 
hormones to affect lipid trafficking, making the 
determination of its actions alone more difficult. There 
are many interacting physiological processes that occur at 
any given time in the human body. Certain available animal 
models may be useful in isolating certain metabolic 
pathways and determining the mode of action of a single 
hormone.
There are two well-known mouse models used to study 
obesity and diabetes. They are the obese (ob/obr described 
below) and diabetic (db/db) mice. The ob/ob mouse is leptin 
deficient, but this deficiency can be rescued by injection 
of leptin because leptin receptors, particularly in the 
brain, are still responsive to leptin (Zhang et al. 1994). 
The leptin receptors of db/db mice are nonfunctional, thus 
the injection of leptin has no effect, i.e. the mice are 
leptin resistant, which seems to be the case for most 
humans (Ghilardi et al. 1996). Therefore, in order for the 
effects of exogenous leptin on obesity to be observed, the 
ob/ob mouse model needs to be used.
The mouse ob gene codes for the protein leptin. This 
protein has an amino acid sequence 84% identical to that 
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found in humans (Zhang et al. 1994). The C57BL/6J ob/ob 
mouse strain was first isolated by Ingalls et al. (1950) 
and was later characterized by Zhang et al. (1994). They 
found ob/ob mice express a twenty-fold increase in abnormal 
ob mRNA that contain a single base substitution resulting 
in a nonsense mutation. This substitution results in a 
truncated leptin protein, leading to leptin protein 
deficiency. The lack of leptin leads to morbid obesity, 
hyperphagia, hypothermia, extreme insulin resistance, 
infertility, and many other endocrine abnormalities 
(Ingalls et al. 1950). The lack of an appetite inhibition 
signal associated with chronic leptin deficiency can cause 
the brain to perceive a starvation status even though there 
are adequate circulating and stored carbohydrates and 
lipids. Thus, the brain continuously stimulates appetite 
and food intake, which leads to obesity (Elmquist et al. 
1998b). The ob/ob mouse model is useful in investigating 
how defects in lipid metabolism (due to reduced 
concentrations of circulating leptin levels) lead to 
serious conditions such as insulin resistance.
The roles of thyroid hormone in regulating 
physiological pathways involved in metabolism, including 
lipolysis, and leptin's role in maintaining the balance 
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between circulating nutrient levels and the quantity stored 
in various tissues, suggest these two hormones may interact 
to affect lipid storage. However, it is not known if the 
actions of leptin are dependent on the presence of thyroid 
hormones. T3 concentrations can be lowered by the drug 
iopanoic acid (IOP), which blocks the activity of type I 
deiodinase, allowing the possibility to study leptin's 
effects in the presence of decreased T3 levels.
Previous Work in Dr. Richard Fehn's Lab
The interactions of thyroid hormone and leptin have 
been studied in Dr. Fehn's lab using both the ob/ob and 
db/db mouse models to evaluate histological and molecular 
data from various tissues. In a study by Brian Underhill 
(2000), C57BL/6J ob/ob mice were treated for nine days with 
saline vehicle, leptin, IOP, or leptin/IOP. He monitored 
daily food consumption, body weight, body heat production 
(measured by radiant body temperature), oxygen consumption, 
respiratory quotient (RQ), and circulating T3 and T4 levels. 
Results revealed that leptin and leptin/IOP treatments 
caused a reduction in food consumption, while IOP treatment 
showed no change. The decrease in body weight was lowest in 
leptin/IOP treated mice, with leptin treatment still 
causing weight loss when compared to vehicle treated mice, 
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and IOP treated mice showing no change. Body heat 
production was increased with leptin/IOP treatment as 
compared to vehicle treatment, but mice treated with leptin 
and IOP alone showed body heat production equal to that of 
vehicle treated mice. Oxygen consumption rates (V02) for 
leptin and leptin/IOP treated mice were the same as the 
vehicle treatment. However, IOP treated mice had a lower V02 
compared to the vehicle treated mice. This suggests that 
leptin prevented the reduction in oxygen consumption 
observed in the IOP treated mice. Furthermore, mice in all 
treatments expressed RQ values representative of lipid 
metabolism. Finally, T3 levels were significantly elevated 
in ob/ob vehicle treated mice compared to ob/+ vehicle 
treated mice, but the remaining three treatment groups in 
ob/ob mice showed no difference among one another. Taken 
together, these results show that reduced body weight in 
leptin and leptin/IOP treated mice may be due ultimately to 
decreased food consumption observed in these groups. IOP 
treated mice may weigh equal to that of vehicle treated 
mice because of the similar food consumption between the 
two groups.
The observation that all of these mice may have been 
primarily utilizing lipid to fuel metabolism may have been
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erroneous. Underhill's results were in contrast with a 
later study by Reno and Fehn (2007) that found that vehicle 
and IOP treated ob/ob mice had an RQ representative of 
carbohydrate metabolism, while leptin treated mice had an 
RQ representative of lipid metabolism. It was also 
suggested by Reno and Fehn (2007) that the lipid metabolism 
by any animal with leptin treatment may have been necessary 
to support their increased production of body heat, which 
is indicative of higher energy expenditure through 
thermogenesis. On the other hand, increased thermogenesis 
could also have been a result of increased lipid 
metabolism.
During periods of increased energy expenditure, lipid 
is the preferred metabolic substrate since lipid is stored 
and readily available for use. All of the animals in both 
studies started out obese, and, therefore, had abundant 
lipid available for use, possibly supporting the notion 
that all animals used lipid metabolism, but Underhill's 
results do not follow the pattern that was seen in the 
later study (Reno and Fehn 2007). For instance, Reno and 
Fehn (2007) saw an increase in lipid metabolism and 
suggested this could support an increase in body heat 
production observed during leptin treatment. Also, the 
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radiant body temperatures in Underhill's study showed that 
leptin/IOP treatment increased body heat production, while 
the other three treatments showed no change. Therefore, his 
results demonstrated that if body heat production is one 
factor that can alter which substrate is used in 
metabolism, then the vehicle, leptin, and IOP treated mice 
should have been using carbohydrates as a metabolic 
substrate if there was no increase in energy as heat.
However, with the exception of IOP treated mice, the oxygen 
consumption rates were relatively constant among the 
treatment groups. Taken together, the results of both 
studies reveal the importance of not one, but many factors 
that underlie whether carbohydrate or lipid metabolism is 
preferred. Moreover, mice may switch between carbohydrate 
and lipid use in a daily cycle depending on whether they 
are active or sleeping (unpublished data from Dr. Fehn's 
lab) .
Another interesting contradiction was found between 
previous studies reported in the literature and research in 
Dr. Fehn's lab in regards to the effects of leptin 
treatment. Pelleymounter et al. (1995) state that ob/ob 
mice of the C57BL/6J strain given leptin increase oxygen 
consumption, while Dr. Fehn's lab (Reno and Fehn 2007;
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Underhill 2000) found no increase in leptin treated mice 
compared to vehicle treated mice. Pelleymounter et al.'s 
study was done on 5-week old mice over a 28 day injection 
period, while the Fehn studies were done on 10-12-week old 
mice over a 9 day injection period. It may be inferred that 
a longer treatment period with leptin may have additional 
affects, but Fehn's lab showed that after nine days of 
treatment, all parameters measured in the mice reach a peak 
and do not go any further. Age effects may also account for 
the differences observed between the studies. For instance, 
the onset of obesity in mice occurs around 5 weeks of age 
and 10-12-week old mice are considered to be reproducti.vely 
mature. My current study will help clarify whether or not 
leptin injection stimulates significant increases in 
metabolism and what effects an increased metabolism may 
have on other measurable parameters such as metabolic 
substrate utilization.
Due to the importance of these factors in evaluating 
the end point analyses of hepatic lipids and adipocytes, 
all of the afore mentioned metabolic parameters need to be 
assessed again in my project. I expect the results in my 
experiments to be a mix of those which found in literature 
(Pelleymounter et al. 1995) and those found in the Fehn lab 
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studies (Reno and Fehn 2007; Underhill 2000) (table 1). My 
study on hepatic lipid content and adipocyte area 
(described below) will provide additional data on the 
relationship between leptin and thyroid hormone in lipid 
metabolism.
Preliminary Work and Hypotheses
Previous work has been done on C57BL/6J ob/ob mice 
where these mice were treated for nine days with vehicle, 
leptin, T3, IOP, 6-hydroxydopanine (6OHDA), leptin/ T3, 
Leptin/6OHDA, T3/6OHDA, and T3/IOP (Reno and Fehn 2007). 
Analysis of hepatic lipid content and lipid droplet size by 
transmission electron microscopy (TEM) and light microscopy 
revealed that treatment groups lacking leptin contained 
more hepatic lipid droplets and larger lipid droplets, 
suggesting lipid storage. In animals treated with 
leptin/6OHDA and leptin/T3, hepatic lipid droplet size and 
content were significantly decreased. (Content was assessed 
by cross-sectional area of hepatocytes.) This suggested 
that leptin is very important in facilitating the breakdown 
and export of stored and newly synthesized lipids because 
it is able to produce its responses even under adverse 
conditions. These were adverse conditions because 
sympathetic neurons are important in energy homeostasis and
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Table 1. Expected Results of Parameters to be Tested.




— T I —
Body weight
— J, —
RQ CHO Lipid CHO Lipid
Food 
consumption — X — 4
IOP treated mice should have the lowest oxygen consumption 
rate while leptin treated mice should have the highest. The 
mice in the remaining two treatment groups should show 
rates of equal value. Body weight should be reduced in 
leptin and leptin/IOP treated mice, while IOP treated mice 
should have body weight equal to that of vehicle treated 
mice. RQ values should reveal that carbohydrates are being 
utilized as a metabolic substrate in the vehicle and IOP 
treated mice, but mice from the other two treatment groups 
that receive leptin should show RQ values representative of 
lipid metabolism. Food consumption should be reduced in 
leptin and leptin/IOP treated mice, while IOP treated mice 
should eat about the same amount as vehicle treated mice. 
--- = no change; j, = decreased values when compared to 
vehicle; CHO= carbohydrate 
hyperthyroidism can lead to further metabolic 
complications. Surprising results were obtained when 
evaluating omental and subcutaneous adipocyte volumes: 
leptin treated mice (alone and combined treatments) had the 
largest adipocyte areas compared to all of the other 
treatment groups. This was interesting given that leptin 
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treatment reduces body weight. It was therefore assumed 
that adipocytes would be smaller than adipocytes from an 
obese mouse given vehicle treatment. One explanation for 
the observed results is that the liver was exporting a vast 
amount of stored lipids and sending them to adipose tissue 
because storing lipids in adipocytes is a more efficient 
way to store excess lipid. This idea is supported by the 
decreased liver lipid content, decreased liver weight, and 
stable glycogen levels in the liver. The stable glycogen 
levels suggest that liver weight was lost not due to an 
increase in metabolism but due to the export of lipids, 
which then moved to adipocytes. This seems logical because 
storage of excess lipid in the liver leads to serious 
problems, such as liver failure and hepatic steatosis 
(displacement of the cytoplasm and organelles due to excess 
lipid accumulation), and adipose tissue is meant to store 
lipid. In this study, total oxygen consumption did not 
increase with leptin treatment, suggesting less lipid 
disposal from adipocytes for metabolism.
Another interesting observation was that IOP treatment 
alone caused massive hepatic steatosis. Analysis of 
hepatocytes under TEM showed apoptosis likely due to 
enlarged lipids distorting organelles, including the 
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nucleus. Interestingly, when IOP treatment was combined 
with T3, large hepatic lipid droplets were still prevalent 
whereas mice treated with T3 alone had numerous small lipid 
droplets. Therefore, the low T3 concentration in IOP treated 
mice may not be the only underlying factor as to why 
hepatic lipids are so large since T3 replacement in a T3/IOP 
combined treatment still exhibited large lipid droplets.
One question that arose was if leptin can cause a 
reduction in hepatic lipid droplet content and size in 
animals that have SNS neuron ablation (Leptin/6OHDA) and in 
animals with excess lipid synthesis (leptin/T3) , then leptin 
should be able- to breakdown large lipid droplets and export 
them even during the massive hepatic steatosis observed in 
IOP treated animals. Thus, a combined treatment of 
leptin/IOP could reveal whether or not low T3 concentration 
has an effect on hepatic lipid transport even in the 
presence of leptin, which as mentioned above has been shown 
to clear the liver of excess lipid under various adverse 
circumstances. If leptin does not decrease hepatic lipid 
size and content in the presence of IOP treatment, then T3 
or some other factor regulated by T3 may be important in 
helping to facilitate the breakdown of lipids in the liver. 
If leptin does decrease hepatic lipid size and content in 
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the presence of IOP treatment, then T3 is not important in 
aiding leptin to export lipids, supporting the vital 
importance of leptin being able to function during 
stressful conditions. It is also expected that adipocyte 
areas will be large in leptin treated mice and in IOP 
treated mice, compared to vehicle treated mice, with IOP 
treated mice possibly having the largest cells. This could 
be expected because leptin treatment should reduce liver 
lipid and store it in adipose cells until utilized in 
metabolism. If oxygen consumption rates are increased in 
the leptin treatment, then adipocyte areas should be 
decreased due to an increased use of adipocytic lipid in 
metabolism. IOP treated mice should have large adipose 
cells because of the extreme lipid storage in the liver and 
adipose tissue and decreased oxygen consumption rates 
previously observed in this treatment. The leptin/IOP 
treated mice should express smaller adipocytes than vehicle 
treated mice, but it is not known if leptin can 
successfully increase metabolism in a low T3 environment or 
how the size of those adipocytes will compare to the mice 
in the leptin and IOP single treatments.
In this thesis, in order to study the effects of 
leptin under both normal and reduced T3 concentration,
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C57BL/6J ob/ob mice were treated for seven days with either 
vehicle, leptin, IOP, or a combination of leptin/IOP. These 
treatments should have resulted in mice with T3 alone 
(vehicle) , leptin 4- T3 (leptin treated) , neither leptin nor 
T3 (IOP treated), or leptin alone (leptin/IOP treated).
These mice were analyzed for changes in total mass-specific 
oxygen consumption, body weight, substrate used in 
metabolism, and food intake over the seven day period. 
Additionally, end point analyses determined omental and 




THE EFFECTS OF LEPTIN AND THYROID HORMONE ON 
METABOLISM AND LIPID TRAFFICKING IN THE 
LIVER AND ADIPOSE TISSUE
OF OB/OB MICE
Introduction
With obesity becoming a world-wide epidemic, it is 
imperative to understand the pathology associated with 
obesity. Obesity is result of the altered control of 
hormones regulating metabolic glucose and lipid trafficking 
pathways (such as leptin and thyroid hormone)(Houseknecht 
1998) . The actions of these hormones are targeted as 
possible routes of therapy to control obesity and its 
complications. Leptin is a hormone secreted by adipose 
tissue in response to fluctuation in cellular energy 
reserves (Tartaglia et al. 1995). Its main role is to act 
as an appetite inhibitor when enough "energy" has been 
taken in. Leptin deficiency would reduce feeding inhibition 
and, therefore, promote obesity. The thyroid hormone 
3,5,3'-triido-L-thyronine (T3) regulates lipogenesis, 
lipolysis, fat storage, and basal oxygen consumption 
rate(Oppenheimer 1991). Since T3 induces an increase in 
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metabolism, which primarily utilizes fatty acids stored in 
adipose tissue, the hormone also induces the production of 
lipids, allowing a reserve to be maintained for the 
increased oxygen consumption rate that results from the 
increased metabolism (Oppenheimer 1991). Low levels of 
thyroid hormone can lead to a decrease in lipolysis, which 
would lead to an increase in body fat stores in adipose 
tissue, and low T3 is associated with low metabolic rate, 
low body temperature, slow heart rate, and weight gain 
(Hadley 2000). Leptin and thyroid hormone are thought to 
interact to control energy homeostasis, but the exact 
interaction(s) is unknown.
Pathologies associated with obesity and diabetes are 
often linked to leptin deficiency or leptin resistance. The 
ob/ob mice of strain C57BL/6J are leptin deficient and thus 
provide a good model to investigate abnormalities related 
to leptin deficiency. Exogenous leptin replacement in ob/ob 
mice has been shown to increase total body energy 
expenditure, decrease food intake, and normalize body 
weight (Halaas et al. 1995; Maffei et al. 1995). However, 
the exact mechanisms leading to these responses are poorly 
understood.
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Thyroid hormone regulates physiological pathways 
involved in metabolism (including lipid metabolism), 
whereas leptin acts to maintain the balance between 
.circulating lipid and glucose levels and the quantity 
stored in various tissues. This suggests that these two 
hormones may interact to affect lipid storage and 
disruption of this interaction may lead to the development 
of obesity. In this thesis, the possible cross-effects of 
leptin and thyroid hormone in obesity were studied in 
leptin deficient ob/ob mice. Individuals were administered 
iopanoic acid (IOP) to reduce thyroid hormone 
concentrations, and leptin, to rescue leptin deficiency. 
Reducing T3 will allow us to assess leptin's ability to 
increase body energy expenditure, decrease food intake, and 
normalize body weight in the presence of low T3 
concentrations. The following changes were assessed in mice 
given leptin, IOP, or a combination of both: oxygen 
consumption, respiratory quotient values, food consumption, 
percent body weight change, omental and subcutaneous 




Twenty 9 week old female mice, strain C57BL/6J ob/ob 
(Jackson Laboratory), were used to analyze variation in 
metabolic expenditures in response to four different 
treatments. Five animals per treatment group were used for 
data analysis (previously shown to be an adequate sample 
size for statistical significance).
The mice were housed individually in a 12:12
light-.dark cycle and allowed access to food ad libitum. On 
the morning of day zero, all mice were given a known 
quantity of normal rodent chow (4% fat). Variation in food 
intake during the treatment period was calculated by 
subtracting the amount of food remaining from the previous 
day's amount. Each mouse was weighed and placed into an 
individual chamber of a flow-through metabolic system 
(AMETEK, AEI Technologies; S-3A/II oxygen and CD-3A carbon 
dioxide analyzers). Air was pulled out of each chamber at 
400 ml/min and analyzed for the fraction of oxygen and 
carbon dioxide content. Excurrent air was passed through 
desiccant to remove any moisture. Each mouse was allowed to 
settle in the chamber for five minutes prior to data 
collection. Readings for each animal were taken in the 
morning (between 06:00- 09:00 hours). Each animal was 
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sampled three times over a 24 miniate period, and the 
average value was used in subsequent analyses. During the 
reading period, the mice were observed for relative 
activity levels that may have affected metabolic readings 
and any behavioral responses to the treatments were 
recorded. Mass specific metabolic rate (total oxygen 
consumption) was calculated as:
Vo2~ (F02 in ~ F02 out) V
Mb
• V02 = the measurement of oxygen uptake, expressed as a 
volume of consumed 02 per minute per gram body mass,
• F02 in = fraction of O2 in the air entering the chamber,
• Fq2 out = fraction of O2 in the air exiting the 
chamber,
• V = the flow rate of air moving through the chamber
(ml/min)
• Mb = body weight (g)
Respiratory quotient (RQ) is a measure of metabolic 
substrate use and can range from 0.71 (lipid utilization) 
to 1.0 (carbohydrate utilization); an RQ of around 0.80 
suggests protein utilization. The RQ value is affected by 
the differences in the amount of energy required to consume 
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a lipid, protein, or carbohydrate, as well as the chemical 
balance of carbon, hydrogen, and oxygen atoms in the 
consumption equation. The RQ was calculated as:
RQ = (Vco2)/(VO2)
• VC02 ~ CO2 production rate
• Vo2 = O2 consumption rate.
Eight channels on the gas analyzer allowed eight mice 
to be sampled at the same time on the same day which 
allowed for increased efficiency in gathering results as 
well as consistency. Due to the relatively constant 
conditions in the animal house, readings done during 
separate time frames would not affect the results because 
they were both done in the morning.
There were five ob/ob leptin deficient mice per group 
in each of the following treatments: vehicle (control for 
handling and injecting mice), leptin (to rescue leptin 
deficiency), IOP (to effectively lower concentrations of 
T3), and leptin/IOP (to observe the affects of leptin in the 
presence of low T3) . (See appendix B for recipes.) Each 
animal was inj ected intraperitoneally (I.P.) with its 
respective drug treatment after the completion of all 
metabolic readings.
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The metabolic analyses and injections were carried out 
over eight consecutive days during the same morning hours 
to control for diurnal variation. Each day, before any 
analysis was done, each animal was checked to ensure that 
no adverse affects were seen due to the treatments. If any 
mouse had symptoms, including extreme exhaustion and 
listlessness, then it was removed from the colony and dealt 
with according to IACUC protocols. This was done in 
addition to observing activity levels during the reading 
periods.
On the eighth day, all of the afore-mentioned 
procedures were carried out with the exception of the 
injections. After morning analyses were complete, all of 
the mice were euthanized with CO2 for tissue collection. 
Blood (ca. 1.0 ml) was collected via cardiac puncture after 
ventilatory arrest, but just prior to cardiac arrest, and 
stored on ice until centrifuged after the dissections. The 
plasma was stored at -80°C. Three pieces (approximately 1 
mm3 each) of the lower left lobe of the liver from each 
mouse were extracted and fixed in 2.5% glutaraldehyde with 
Tyrode's Cacodylic acid for TEM embedding (see appendix C). 
The remainder of the liver was frozen and stored in liquid 
nitrogen. Omental and subcutaneous adipose tissues were 
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frozen and stored in liquid nitrogen until analysis of cell 
cross-sectioned area. Small pieces (size irrelevant) of the 
omental and subcutaneous adipose tissues were taken, placed 
on a microscope slide, stained with methylene blue, and 
examined and photographed using light microscopy at 200x 
magnification. Multiple images were captured per slide 
using NIH Image and later analyzed for adipose cell areas 
using ImageJ. Ten cells per tissue were analyzed, and the 
average cell cross-sectioned area was taken as 
representative.
Size and distribution of liver lipid droplets were 
analyzed using the TEM embedded tissues. The osmium 
tetroxide fixative stains the lipids black and allows for 
analysis of lipid content. The tissues were sectioned to a 
thickness of 900 nm using an ultramicrotome. The sections 
were placed on a microscope slide and examined using light 
microscopy at 400x and lOOOx magnification. NIH Image was 
used to capture three images per slide per magnification, 
and ImageJ was used to determine lipid droplet sizes and 
content in hepatocytes.
All data were analyzed using one way analysis of 
variance (ANOVA) in Sigma Stat (Systat Software, Inc. 
2004). Where relevant, nested ANOVA was performed, i.e.
44
lipid droplet size was modeled by group and mouse. This 
allowed the data from three separate cross-sections per 
mouse to be analyzed for group effects more efficiently. 
Pairwise comparisons were done with Tukey's test. Dunn's 
test was used to compare multiple points against a control 
group. Linear regression analyses were performed between 
all variables observed in the study, between groups and 
within groups between days. Where relevant, linear 
regressions were run with parameters assessed and food 
consumption to control for the alterations that might occur 
based on eating habits. Post-hoc corrections (Bonferroni) 
were done on all data not subjected to Tukey's test. Data 




The morning of the first day of injections (day 1), 
all of the twenty mice had high activity levels and were 
eating normally. By day two, all of the mice in the IOP and 
leptin/IOP treated groups were lethargic and had stopped 
eating. Two animals from each of those groups died on days 
four and five. Since the cause of death from these animals 
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is not completely certain, all of the data for those 
individuals were omitted from the analyses. The final 
sample size per group was as follows: vehicle (veh): 5, 
leptin (lep): 5, iopanoic acid (IOP): 3, and 
leptin/iopanoic acid (lep/IOP): 3.
Body Mass
To normalize for differences in body weight among all 
the mice on day zero (figure 3), body mass change was 
analyzed by starting at 100 percent on day zero and either 
adding or subtracting percent change for each treatment 
group as they either gained or lost weight, respectively. 
The body mass of vehicle and leptin treated mice did not 
change whereas IOP and leptin/IOP treated mice lost weight 
(P < 0.016 and p < 0.008, respectively; figure 4). The mice 
in the vehicle group ate steadily every day and showed a 
correlation of increased body mass with time (see below). 
The lack of weight gain in mice in the leptin group 
suggests that leptin inhibited appetite. Ob/ob mice do not 
produce leptin and therefore vehicle treated mice can 
continue to gain weight. However, the body mass for this 
group was not significantly greater from day 0.
The relative change in weight between the mice in the 
leptin treatment and leptin/IOP treatment were
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Day 0 vs. Day 7 Mean Body Weight 
#
Figure 3. Day 0 vs. Day 7 Mean Body Weight. Statistica 
analyses show that IOP and leptin/IOP treated mice 
weighed less on day 7 than vehicle treated mice. 
Leptin/IOP treated mice also weighed less than leptin 
treated mice.
*Significant differences in body mass of the groups 
compared to the vehicle treated group.
#Also significantly different was leptin vs. 
leptin/IOP; p < 0.05
Values are mean ±SEM. For vehicle and leptin, n=5. For 
IOP and leptin/IOP, n=3.
significantly different from each other after seven days (p 
< 0.008), while no other combinations revealed significant 
differences among one another. The vehicle and leptin/IOP 
treated mice showed a significant relationship between 
change in body mass and day of trial (r2= 0.959, p< 0.04 and 
r2= 0.997, p< 0.024, respectively; figure 5). The leptin 
treated mice did not fluctuate in weight during the study 
(r2= 0.0072, p < 0.928). The IOP treated mice lost weight
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Percent Change in Body Weight After 7 Days
B p values from ANOVA results and Tukey's test




Leptin/IOP 0.008 0.008 0.228
Figure 4. Percent Change in Body Weight After Seven Days 
of Treatment. Data are normalized to body mass on day 0.
A. Vehicle and leptin treated mice showed no difference 
in weight change during the treatment period, while the 
IOP and leptin/IOP treated mice lost weight.
B. p values from ANOVA results and Tukey's Test. 
*Significant differences of percent weight change in the 
groups compared to the vehicle treated group after the 
treatment period.
#Also significantly different was leptin vs. leptin/IOP; 
p < 0.05
Values are mean ±SEM. For vehicle and leptin, n=5. For 
IOP and leptin/IOP, n=3.
during the first three days, likely due lack of food 
consumption associated with treatment, but by day four, two 
of the three mice still alive recovered and were gaining
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B Linear Regression Results
Vehicle Leptin IOP Leptin/IOP
r2 0.515 0.00720 0.313 0.950
F 40.4 0.00826 10.0 417
P 0.04* 0.928 0.096 0.024 *
Figure 5. Percent Weight Change Per Day of Treatment.
A. Vehicle treated mice showed a tendency of increasing 
body weight over the treatment period. Leptin/IOP treated 
mice showed a tendency of decreasing body weight. Leptin 
treatment did not affect weight during the treatment period 
and IOP treated mice showed no tendency of either 
decreasing or increasing weight. The equations of the lines 
for the vehicle, leptin, IOP, and leptin/IOP groups were as 
follows: y= l.llx + 99.08, y = -O.Olx + 100.1, y = -1.27x + 
96.18, and y = -3.25x + 99.20, respectively. For vehicle 
and leptin, n=5. For IOP and leptin/IOP, n=3.
B. Table of r2, F, and p values from linear regression 
analyses of daily percent weight change versus day of 
treatment.
weight. Given that one mouse in this group did not show the 
same trend and given the small sample size, the body weight 
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for this group is not strongly correlated with day of 
treatment (r2= 0.683, p < 0.096).
Food Consumption
Daily food consumption was analyzed to detect the 
effects of the treatments on the regulation of appetite. 
Analysis of food consumption began after the first 
treatment day; therefore, there are no data for pre­
treatment food consumption; however, food consumption was 
determined daily for the time during the treatment.
The body mass normalized average daily food 
consumption was significantly lower in the IOP and 
leptin/IOP treated mice relative to control mice (p < 0.05; 
figure 6). Furthermore, the leptin/IOP treated mice 
consumed less food than the leptin and IOP treated mice. 
Since the IOP and leptin/IOP treated mice became ill, the 
decreased food consumption seen in these groups may not be 
from the treatments directly but due to illness. Some of 
the animals in the IOP group recovered after day three and 
started eating again, but one mouse in this group did not 
eat during the entire treatment period. Therefore, the 
small sample size (n=3) may be a factor as to why decreased 
food consumption was observed counter to expectations.
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Mean Daily Food Consumption



















Figure 6. Mass-Specific Mean Daily Food Consumption. Mean 
daily food consumption per body weight showed that the IOP 
and leptin/IOP treated mice ate less on average per day 
than the vehicle and leptin treated mice. Although, a 
slight decrease in food consumption is seen in the leptin 
treatment, this was not significant.
^Significant differences with groups against the vehicle 
treated group.
#Also significantly different were leptin vs. leptin/IOP, 
IOP vs. leptin/IOP; p < 0.05.
Values are mean ±SEM. For vehicle and leptin, n=5. For IOP 
and leptin/IOP, n-3. MB = body mass weight
The mean food consumption after the seven day treatment 
period varied between all groups. Leptin treated mice ate 
less total food than vehicle treated mice, but this was not 
significantly different. However, total food consumed by 
both the IOP and leptin/IOP treated mice was significantly 
less than food consumed by vehicle treated mice (p < 0.05, 
data not shown). On day one of treatment, the IOP and 
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leptin/IOP treated mice ate less food than vehicle treated 
mice (p < 0.05, figure 7). Only the vehicle treated mice 
significantly changed their rate of food consumption over 
the study period (p < 0.05, figure 7). However, the 
remaining IOP treated mice did start eating more after the 
fourth day of treatment and, therefore, have a higher mean 
food consumption on day seven. While the difference is not 
significant between day 1 and day 7 food consumption for 
IOP treated mice, it can be supported by the relationship 
between food consumed and day of trial (see below).
Vehicle and IOP treated mice increased mean daily food 
consumption over the seven day treatment period (p < 0.005 
and p < 0.015, respectively; figure 8). This suggests that 
the IOP treated mice may have been moving towards the same 
or greater rate of food consumption as the vehicle treated 
mice. Therefore, the initial low amount of food consumption 
seen in the IOP group may have been because the animals in 
that group were sick and not because of the effects low T3. 
The leptin and leptin/IOP treated mice showed no trends 
towards changing food consumption as a result of their 
treatment.
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■ Day 1 
EDay 7
Figure 7. Mean Daily Food Consumption on Days 1 and 7 of 
the Treatment Period. Compared to vehicle treated mice, 
the IOP treated mice ate less food on day 1, and 
leptin/IOP treated mice ate less on day 1 and day 7. On 
day 7, the leptin treated mice consumed less food 
compared to the vehicle group, but this was not 
significant.
#Significant difference between food consumption on day 
1 and day 7.
*Significant differences with groups relative to the 
vehicle treated group for the same day. Also 
significantly different on day 1 were leptin vs. 
leptin/IOP, leptin vs. IOP and on day 7 were leptin vs. 
leptin/IOP, leptin vs. IOP; p < 0.05.
Values are mean +SEM. For vehicle and leptin, n=5. For 
IOP and leptin/IOP, n=3.
Oxygen Consumption and RQ
Metabolic rates were determined daily using a flow- 
through metabolic system. There were no differences in 
mass-specific oxygen consumption between any of the 
treatment groups on day 7 (figure 9). All groups maintained 

















B Linear Regression Results
Vehicle Leptin IOP Leptin/IOP
0.286 0.135 0.372 0.0013
F 13.22 5.135 11.27 0.0247
E 0.005 * 0.150 0.015* 0.877
Figure 8. Mass-Specific Daily Food Consumption.
A. Trend of average food consumption throughout the seven 
day treatment period. The vehicle and IOP treated mice 
showed a tendency of increasing mean daily food consumption, 
p < 0.005 and p = 0.015, respectively, while the leptin and 
leptin/IOP treated groups showed no change over the 7 day 
treatment period. The equations of the lines for the 
vehicle, leptin, IOP, and leptin/IOP groups were as follows: 
y = 0.0096x + 0.0766, y = 0.0033x + 0.0743, y = 0.0142x - 
0.0106, and y = -7E-05x + 0.0019, respectively.
Mb= body weight
Values are mean. For vehicle and leptin, n=5. For IOP and 
leptin/IOP, n=3.
B. r2, F and p values of the treatment groups for linear 
regression analysis of trends during the seven day treatment 
period.
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Figure 9. Oxygen Consumption on Days 0 and 7 of the 
Treatment Period. On day 0, leptin and IOP treated mice 
consumed less oxygen than vehicle treated mice (p < 0.007 
and p < 0.012, respectively). There were no differences 
compared to vehicle treated mice for any groups on day 7. 
Leptin treated mice consumed more oxygen on day 7 than on 
day 0.
*Significant differences with groups relative to the 
vehicle treated group for the same day.
#Significance on day 0 vs. day 7 for lep, p < 0.05. 
Values are mean ±SEM. For vehicle and leptin, n=5. For 
IOP and leptin/IOP, n-3.
consumption (0.030 ± 1.6 x 10"3 ml02-min-1 *g-1) during the 
seven days. Surprisingly on day zero, leptin treated mice 
and IOP treated mice had lower mass-specific oxygen 
consumption rates than vehicle treated mice (p < 0.007 and 
p < 0.012, respectively; figure 9). Leptin treated mice 
also consumed more oxygen on day 7 than on day 0 (p < 
0.012). Eating, time of day, and activity levels are all 
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known to affect rate of oxygen consumption. Since day zero 
was before any treatment, all of the oxygen consumption 
rates should have theoretically been similar since all of 
the mice exhibited similar eating and activity patterns on 
day zero, and the metabolic tests were.done at the same 
time. Therefore due to the variability observed, these data 
may not be accurate.
The ratio of CO2 production to O2 consumption (RQ) 
changes based on the substrate being oxidized and thus may 
allow for a better understanding of lipid and glucose 
trafficking. The RQ for the leptin treated mice decreased 
over the seven day treatment period (p < 0.015), while the 
RQ of other groups did not show any change on a day- to-day 
basis (data not shown). On day 7, the leptin and IOP 
treated mice had lower RQ values compared to day zero (p < 
0.016 and p < 0.048, respectively; figure 10). No other 
groups had significantly different RQ values between day 0 
and day 7. Compared to vehicle treated mice on day 7, 
leptin/IOP treated mice had a lower RQ indicative of lipid 
metabolism (figure 10). It is not known if this was a 
treatment affect. The lower RQ may have been due to the 
fact that animals from this group did not eat so their only 
source of energy would have been reserves in adipose
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Day 0 vs. Day 7 Mean Respiratory Quotient




Figure 10. Respiratory Quotient (RQ) on Days 0 and 7 of the 
Treatment Period. On day 0, IOP treated mice had an RQ 
higher than the vehicle treated mice. On day 7, vehicle, 
leptin, and leptin/IOP treated mice had an RQ of about 
0.85. This suggests that the mice were utilizing a mixture 
of carbohydrates and lipids to fuel metabolism. Leptin/IOP 
treated mice had an RQ of 0.79 after the treatment period, 
suggesting these mice were utilizing mostly lipids in 
metabolism.
^Significant difference on day 0 for vehicle vs. lep and 
vehicle vs. IOP, and day 7 for vehicle vs. leptin/IOP. Also 
significant on day 7 was leptin vs. leptin/IOP.
#Significance on day 0 vs. day 7, p < 0.05.
Values are mean ±SEM. For vehicle and leptin, n=5. For IOP 
and leptin/IOP, n=3.
stores. The leptin and IOP treated mice had RQ values 
similar to that of the vehicle treated mice after seven 
days, all of which were indicative of a mixture of both 
carbohydrate and lipid metabolism. As with oxygen 
consumption, day zero RQ was highly variable (1.05 + 0.12) 
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among the mice even though this was pre-treatment. 
Therefore, experiments on RQ need to be repeated to 
understand the implications of RQ from these drug 
treatments.
Adipose Tissue
Omental adipose tissue is found near the stomach and 
spleen and can extend into the rest of the abdominal 
cavity. Adipocyte sizes fluctuate depending on nutrient 
availability. Relative to vehicle treated mice, leptin 
treated mice had larger adipocyte areas (p < 0.05), 
leptin/IOP treated mice had smaller adipocyte areas (p < 
0.05), whereas the IOP treated mice were not different from 
vehicle treated mice (figure 11A, 12). It is not known 
whether the decrease in adipocyte area for the leptin/IOP 
treated mice was due to reduced food consumption or to the 
treatment. The leptin/IOP treated mice would have been 
expected to have adipocyte areas in between those of leptin 
and IOP treated mice, not lower, suggesting that the 
results seen for this group are due to starvation. During 
starvation, lipids stored in adipocytes are metabolized to 
support whole-body energy consumption.
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A Omental Adipocyte Area
B Subcutaneous Adipocyte Area
Figure 11. Omental and Subcutaneous Adipocyte Area.
A. Omental adipocyte area among the different 
treatment groups. Relative to vehicle treated mice, 
leptin treated mice had larger adipocyte areas, IOP 
treated mice had similar adipocyte areas, and 
leptin/IOP treated mice had smaller adipocyte areas.
B. Subcutaneous adipocyte area among treatment 
groups. Subcutaneous adipocyte area in the 
leptin/IOP group decreased compared to the vehicle 
group. Leptin and IOP treated mice had cell sizes 
similar to that of vehicle treated mice.
*Significant differences relative to vehicle treated 
mice. #Also significantly different were in A: 
leptin vs. leptin/IOP; in B: leptin vs. leptin/IOP, 
p < 0.05. Values are mean ±SEM. For vehicle and 
leptin, n=5. For IOP and leptin/IOP, n=3.
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Figure 12. Omental Adipose Tissue Viewed Under the 
Light Microscope.
A: vehicle treated mice; B: leptin treated mice; C: IOP 
treated mice; D: leptin/IOP treated mice. Leptin 
treated mice had the largest adipocyte area, leptin/IOP 
treated mice had the smallest, and IOP treated mice had 
similar adipocyte area relative to vehicle treated 
mice.
Ten different fields of view were taken per animal at 
200x.
Subcutaneous adipose tissue is the fat storing tissue 
found just beneath the surface of the skin. This fat is 
mainly used for insulation and long-term storage of lipid. 
Subcutaneous adipose stores are the primary source for 
lipids utilized during starvation; however, omental adipose 
stores can still be used (Wajchenberg 2000). However, there 
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were no significant correlations observed between omental 
adipocyte area and relative weight change.
The large omental adipocytes observed in leptin 
treated mice may be indicative of lipid be taken away from 
peripheral tissues that may have exhibited excess fat 
before treatment (because they are obese), but with leptin 
treatment they are able to redirect the lipid to omental 
adipose tissue for temporary storage. IOP treatment had no 
effect on the average area of individual adipocytes, 
suggesting that low thyroid hormone does not affect lipid 
storage in omental fat.
The leptin/IOP treated mice had the smallest area per 
cell in subcutaneous adipocytes; these mice had 
significantly smaller cells than both the vehicle and 
leptin treated mice (p < 0.05, figure 11B, 13D). The area 
of subcutaneous adipocytes in IOP treated mice was not 
different from either vehicle or leptin treated mice 
(figure 13).
The subcutaneous adipocytes in mice in the leptin/IOP 
group may have been acting as the primary energy source for 
these mice because they did not eat during the treatment 
period. This idea could be supported by a positive 
correlation between mean daily food consumption
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Figure 13. Subcutaneous Adipose Tissue Viewed Under the 
Light Microscope.
A: vehicle treated mice; B: leptin treated mice; C: IOP 
treated mice; D: leptin/IOP treated mice. Leptin and 
IOP treated mice had similar adipocyte areas to vehicle 
treated mice, while leptin/IOP treated mice had a 
smaller adipocyte area.
Ten pictures were taken per animal at 200x.
(g food/day/g Mb) and subcutaneous adipocyte areas in the 
leptin/IOP group; however this relationship turned out to 
be insignificant (p = 0.093, r2 = 0.998, F = 416) because 
food consumption was about zero for these mice. These two 
variables were not correlated in any other group.
The average area of subcutaneous adipocytes in the 
leptin and IOP treated mice did not change relative to the 
vehicle mice. It was hypothesized that IOP treated mice 
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would show an increase in the subcutaneous adipocyte area 
because low levels of thyroid hormone reduce lipolysis 
(Oppenheimer 1991; Pou 1989). Since the mice in this group 
were sick at the beginning of the study, the area of the 
adipocytes may have decreased as these cells were providing 
lipids for energy. As these mice started eating again, the 
cell area increased. The mice treated with leptin were 
expected to have a decrease in subcutaneous adipocyte area 
as leptin acts to stimulate lipolysis and induce weight 
loss in obese mice (Halaas et al. 1995; Maffei et al.
1995). The results support the idea that subcutaneous lipid 
is primarily metabolized when energy supply is low. Since 
food was available and mice in the vehicle, leptin, and IOP 
groups all ate, their subcutaneous adipocyte area remained 
the same.
Hepatic Lipids
The liver stores lipids in small intracellular 
droplets. Both the size of the droplet and the total amount 
of lipid in the cell vary with metabolic demand. Total 
hepatic lipid droplet (LD) content was determined by 
calculating the cross-section area of LD in a cell (figure 
14). It was seen that leptin treated mice had the least 
amount of lipid while leptin/IOP treated mice had the most
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Figure 14. Hepatic Lipids Viewed Under the Light 
Microscope.
A: vehicle treatment; B: leptin treatment; C: IOP 
treatment; D: leptin/IOP treatment. Compared to vehicle 
treated mice, leptin treated mice had less, and leptin/IOP 
treated mice had more, hepatic lipid, while hepatic lipid 
in IOP treated mice was similar.
TEM embedded, osmium tetroxide post-fixed livers sectioned 
at 900 nm and viewed at lOOOx.
(p < 0.05; figure 15). The IOP treated mice had relatively 
similar lipid content as the vehicle treated mice.
Moreover, hepatic cells from both the leptin treated mice 
and IOP treated mice contained significantly less lipid 
than those cells from the leptin/IOP treated mice (p < 
0.05).
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vehicle treated mice, leptin treated mice had less 
lipid droplet content, IOP-treated mice had the 
similar amounts of lipid droplet content, and 
leptin/IOP treated mice had more lipid droplet 
content.
*Significant differences with groups against the 
vehicle treated group. #Also significantly 
different were leptin vs. leptin/IOP, IOP vs. 
leptin/IOP; p < 0.05.
Values are mean ±SEM. For vehicle and leptin, n=5. 
For IOP and leptin/IOP, n=3.
I predicted that a treatment combining leptin and IOP 
should result in a metabolic profile similar to leptin 
treatment alone. The hepatocyte lipid content seen in the 
present study showed that leptin treatment caused a 
reduction in the amount of total lipid in the liver where 
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IOP treatment of leptin-deficient mice caused no change in 
lipid content, confirming previous research (Reno and Fehn 
2007) . The results from the leptin/IOP treatment were 
contradictory to expected. The total lipid content in the 
liver actually increased; therefore, the prediction that 
leptin would rescue steatosis in mice with a low thyroid 
hormone concentration was shown to be incorrect. This 
suggests that thyroid hormone may be an important factor 
involved in controlling hepatic lipid breakdown and/or 
export, as supported by Mukhopadhyay et al. (2003).
Hepatic LDs were categorized into two groups: small (< 
100 pm2) and large (> 100 pm2) , as done previously (Reno and 
Fehn 2007), because these are arbitrarily the two main 
groups of lipid droplets in the liver. All of the 
treatments caused a large number of small LDs in the liver, 
most likely because all mice are synthesizing lipid, just 
at various rates. Furthermore, the sizes of individual LDs 
within the < 100 pm2 class were all different among the 
groups (p < 0.05; figure 16A) . IOP treated mice had smaller 
LDs than the vehicle treated mice, while the LDs in leptin 
and leptin/IOP treated mice were larger than the vehicle 
treated mice.
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Figure 16. Small Liver Lipid Droplets.
A. Analysis of small LDs showed that leptin, IOP, and 
leptin/IOP treated mice had small LDs of different sizes 
compared to the vehicle group. Of all the small LDs, the 
leptin/IOP group had the largest LDs and the IOP group 
had the smallest. The leptin group had larger LDs than 
the vehicle group.
B. Total small liver LD area covered. Leptin treated 
mice showed more small LDs relative to vehicle treated 
mice. IOP and leptin/IOP treated mice had livers covered 
in similar amounts of small LDs to vehicle treated mice. 
^Significant differences against the vehicle treated 
group. #Also significantly different were in A: leptin 
vs. IOP, leptin vs. leptin/IOP, IOP vs. leptin/IOP; in 
B: leptin vs. IOP, IOP vs. leptin/IOP, p < 0.05.
Values are mean ±SEM. For veh and lep, n=5. For IOP and 
lep/IOP, n=3.
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The various small LDs seen within the small size 
category are thought to be indicative of lipid synthesis, 
but also could be representative of the breakdown of larger 
(> 100 pm2) LDs for lipid export. Leptin treated mice were 
expected to have the smallest LDs of all the groups and 
leptin/IOP treated mice to have slightly larger LDs because 
the effects of low T3 would cause less hepatic lipid 
breakdown, leading to larger LDs (Mukhopadhyay et al. 
2003). LDs in IOP treated mice were not expected to change 
from those in vehicle treated mice. Even though all groups 
had small LDs, the total areas of a cell covered by small 
LD's were different. The visual analyses were supported by 
a nested ANOVA (figure 16B). The hepatocytes of leptin 
treated mice had the most area covered by small LDs while 
the hepatocytes covered by small LDs in IOP and leptin/IOP 
treated mice were not different relative to the vehicle 
treated mice. However, the IOP treated mice had less 
hepatic area covered by small LDs relative to leptin and 
leptin/IOP treated mice (p < 0.0002 and p < 0.016, 
respectively). The livers of IOP treated mice may have had 
smaller small LDs because their livers contain mostly large 
LDs (discussed below), which indicates lipid storage. While 
the small LDs are present in all groups, they may not be as 
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important in understanding hepatic lipid content as large 
LDs (see below).
Within the class of LD > 100 pm2, leptin treated mice 
had the smallest LD (mean= 200 pm2, p < 0.05; figure 17A) . 
The large LDs in this class from the TOP and leptin/IOP 
treated mice were also significantly larger than those of 
the leptin treated mice (p < 0.05), but not from one 
another or the vehicle treated mice.
The fact that livers of leptin treated mice had the 
smallest LDs within the large LD class once again suggests 
leptin acts to decrease the size of these larger LDs in 
obese mice, breaking them down for export and/or (5- 
oxidation. In leptin treated mice, small LDs (mean= 15 pm2) 
predominated over large LDs (mean= 200 pm2) . It was not 
expected that LDs in the IOP and leptin/IOP groups would be 
about the same size as those of the vehicle treated mice. 
However, while the average size of these storage droplets 
may be relatively similar, the total area taken up by large 
LDs was different between the groups (figure 17B). The area 
covered by large LD in IOP treated mice was a similar 
amount to vehicle treated mice, but significantly greater 
than the leptin treated mice (p < 0.0007). The leptin/IOP 
treated mice had more area covered by large LDs than all
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Veh Lep IOP Lep/lOP
Treatment Group
B Total Liver Area Covered by Large Liver Lipid
Figure 17. Large Liver Lipid Droplets.
A. Large liver lipid droplets show that the leptin 
group has the smallest lipid droplets in the large LD 
group. The IOP and leptin/IOP groups had lipid 
droplets not different from the vehicle group.
B. Total large liver LD area covered. Leptin treated 
mice had less hepatic large LDs, while leptin/IOP 
treated mice had more hepatic large LDs than vehicle 
treated mice. IOP treated mice had similar area 
covered in liver with large LDs relative to vehicle 
treated mice.
^Significant differences against the vehicle treated 
group.
#Also significantly different were leptin vs. IOP, 
leptin vs. leptin/IOP, p < 0.05. Values are mean ±SEM. 
For vehicle and leptin, n=5. For IOP and leptin/IOP, 
n=3.
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other groups (p < 0.00001). The inability of leptin/IOP 
treated mice to break down the large LDs suggests that the 
action of leptin was hindered, possibly by the lack of 
thyroid hormone.
Taken together, the quantity and sizes of hepatic LDs 
suggest that while leptin treatment alone can reduce large 
LDs, the leptin/IOP combined treatment cannot. The greater 
total lipid content and the larger LDs observed in the 
leptin/IOP group provide more evidence for a possible 
leptin/thyroid hormone interaction. As mentioned earlier,
j
previous research (Reno and Fehn 2007) suggests leptin has 
the ability to reverse the effects of obesity during 
adverse conditions, such as sympathetic neuron ablation and 
hyperthyroidism, whereas a low thyroid hormone environment 
in obese mice causes massive hepatic steatosis. Although 
IOP treated mice did not have more lipid or larger LDs than 
the vehicle group in this study, the hepatic lipid content 
in both of these groups is still very high (about 60-80% 
more lipid than a normal (ob/+) mouse). Since leptin 
replacement in conjunction with IOP did not decrease the 
quantity or size of the lipids as it does when given alone, 
the lowered T3 levels are likely inhibiting the action of 
leptin. Thus thyroid hormone may be an essential factor 
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that works in concert with leptin to regulate hepatic lipid 
trafficking (i.e. T3 may be permissive to leptin).
Conclusion
The effects of leptin and thyroid hormone on various 
metabolic parameters were studied in leptin-deficient obese 
mice. Exogenous leptin decreased liver lipid content, 
reduced liver lipid droplet sizes, and increased the size 
of omental adipose cells. All of these results confirm 
previous studies showing leptin has the ability to reduce 
excess lipid storage in the liver by shuttling lipid to 
adipocytes. Although the IOP and leptin/IOP treated mice 
became ill, this experiment still provides insight into the 
role of thyroid hormone in lipid trafficking. IOP treatment 
alone produced results similar to the control mice with 
regards to lipid storage in adipose tissue and liver, and 
the leptin and leptin/IOP treated mice showed opposite 
results to one another. Therefore, comparisons among the 
leptin, IOP, and leptin/IOP groups can still be made. The 
IOP treated mice were not different from the vehicle 
treated mice with regards to adipose tissue and liver lipid 
storage. Oddly, when leptin and IOP were combined, 
significant decreases were seen in omental and subcutaneous 
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adipocyte areas and increases in liver lipid content, which 
indicated excess lipid storage. This is surprising because 
my working hypothesis was that giving leptin to an obese 
animal in a low thyroid hormone environment should produce 
results that reflect a reversal of excess lipid storage 
that occurs in the IOP treatment alone. The mice in the 
combined leptin/IOP treatment actually had increased 
hepatic lipid content and lipid droplet size, but had the 
smallest adipocyte areas. The hepatic lipid should have 
been exported and lipid storage should have taken place in 
adipose tissue only. Since this occurred in the leptin 
treated mice and did not occur in the IOP treated mice, 
this suggests lack of thyroid hormone is the limiting 
factor regarding the ability to export hepatic lipids or to 
use them for 0-oxidation.
Thyroid hormone is an important regulator of 
metabolism, and this study provides further evidence that 
it is essential in lipid trafficking in the liver. Further 
studies should be conducted that analyze thyroid hormone 
effects in other tissues to obtain a better picture of its 
role in whole-body metabolism. Further study is also needed 
to understand the role of thyroid hormone in the export 
mechanisms of hepatic lipids, especially the proteins that 
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DISCUSSION OF CONCLUSIONS COMPARED
TO PREVIOUS WORK
Discussion
In the present study, leptin-deficient obese mice were 
used to study how the hormone leptin acts on lipid 
metabolism in a low thyroid hormone environment. Metabolic 
parameters examined were food consumption, weight change, 
mass-specific oxygen consumption, respiratory quotient 
(RQ), omental and subcutaneous adipocyte areas, and hepatic 
lipid content and size.
Metabolic rate can be estimated from the rate of 
oxygen consumption (V02) • Metabolic rate can be affected by 
numerous factors, including food intake, activity levels, 
and time of day. This study attempted to minimize variation 
in metabolic rate from these factors. All of the animals 
were allowed access to food day and night while in their 
cages. While in the metabolic flow-through chambers, all 
animals did not have access to food and their relative 
activity levels were noted. All mice were in the chambers 
for approximately eight minutes before measurements were 
taken to acclimate them to unfamiliar surroundings.
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Furthermore, the metabolic rates were measured in the early 
morning hours every day. However, in spite of attempting to 
minimize these variations, there were large differences in 
pre-measurement food consumption and relative activity 
levels in the chambers.
Mass-specific oxygen consumption was highly variable 
among all twenty mice (even on day zero) before any 
injections were given. The RQ values were similarly 
variable. Due to this variation, the data from both oxygen 
consumption and RQ are suspect. However, all mice had a 
similar rate of mass-specific oxygen consumption on day 
seven. The RQ values on day seven were also similar (RQ = 
0.86 ± 0.012) for all groups except leptin/IOP treated 
mice, which had a lower RQ (0.78), suggestive of 
metabolizing lipids. These mice had not eaten over the 
whole treatment period and stored lipids would have been 
their only source for energy. The rest of the groups had 
similar RQ values indicative of a mixture of lipid and 
carbohydrate metabolism.
Leptin is known to suppress appetite, increase 
metabolic rate, and cause an obese mouse to lose weight 
(Halaas et al. 1995; Maffei et al. 1995). The leptin 
treated mice in the current study did not decrease food 
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consumption during the treatment period compared to vehicle 
treated mice. However, closer examination of the data 
suggest that if the treatment had been continued over a 
longer period the leptin treated group would have exhibited 
significantly decreased food consumption. Unpublished work 
from Dr. Fehn's lab suggests that a leptin effect on food 
consumption becomes evident after nine' days of treatment. 
This is supported by the difference in food consumption 
between vehicle and leptin treated mice shown in the trend 
line in figure 8. Furthermore, leptin treated mice did not 
decrease in body mass during the treatment. However, the 
vehicle treated mice did gain weight; therefore, leptin may 
have been acting to inhibit weight gain. Mean daily food 
consumption by the leptin treated mice was strongly 
correlated to final weight change on day seven. Leptin may 
have caused a reduction in food intake relative to control 
mice, which, in turn, reduced how much weight they gained.
Terminal analysis of omental adipose tissue and 
hepatic lipids showed that leptin treated mice had the 
largest adipocytes and the lowest hepatic lipid content. 
Furthermore, hepatic LDs were mostly small with the largest 
LDs still smaller than the other groups' large LDs. Taken 
together, these results suggest that leptin promoted the 
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breakdown of large LDs in the liver which led to 
exportation of the resulting small LDs to the adipocytes or 
utilization in p-oxidation. These results agree with those 
from previous work on ob/ob mice (Reno and Fehn 2007) .
Since the IOP and leptin/IOP treated mice stopped 
eating during the treatment period, starvation effects must 
be taken into account during analysis of their data.
Starvation can alter the physiological status of an animal.
During starvation, glucose produced by the liver and 
kidneys is primarily used by the central nervous system as 
an energy source (Neumann-Haefelin et al. 2004). Fatty 
acids released from adipose stores are used for energy by 
peripheral tissues, such as heart, skeletal muscle, and 
liver. This occurs through fatty acid oxidation and through 
the oxidation of ketone bodies, which are by-products of 
excess fatty acid breakdown in the liver (Neumann-Haefelin 
et al. 2004). Furthermore, acute starvation is known to 
cause an increase in secretion of insulin, growth hormone, 
and glucagon leading to hypoglycemia (Goodman 1961). 
Starvation stimulates adipose tissue to break down 
triglyceride to free fatty acids (Goodman 1961). Therefore, 
due to the increased lipid mobilization from fat stores, 
the respiratory quotient (RQ) should be close to 0.7, 
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indicative of lipid metabolism (Von Pettenkofer 1966). 
During starvation, metabolic expenditure, i.e. oxygen 
consumption, is decreased (Therriault 1968). Therefore, the 
mice that stopped eating were expected to have smaller 
adipocytes due to starvation alone and not necessarily due 
to the effects of the treatments. Moreover, these mice 
would be expected to have a lower metabolic rate, which may 
cause the lipids released from adipose tissue to accumulate 
in other tissues.
Only the leptin treated mice showed a correlation 
between mean daily food consumption and body weight, as 
well as mean daily food consumption and the size of 
subcutaneous adipose cells. However, while the IOP and 
leptin/IOP treated mice ate less and lost a relatively 
large amount of body weight, there were no correlations 
between those variables and either of the groups. The IOP 
treated mice most likely did not show a relationship 
between the two variables because two of the three mice 
that remained in that group started eating and gaining 
weight back by day four. The one mouse that did not show 
this pattern may have skewed the data. An ANCOVA analysis 
of food consumption revealed that this one mouse was 
significantly different from the other two in the group.
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However, due to the small sample size, this mouse was not 
excluded from the analyses. The leptin/IOP treated mice 
stopped eating all together. Thus, there would be no 
correlation with weight change because food consumption 
stayed at zero throughout the study. Therefore, the 
decrease in body mass in the IOP and leptin/IOP groups 
cannot be directly attributed to the amount of food (or 
lack thereof) consumed.
The leptin treated mice were expected to lose weight, 
while the IOP treated mice were expected to gain weight. 
Neither of these predicted outcomes occurred. However, the 
IOP treated mice which recovered showed a possible trend 
towards increasing body mass that may have become 
significant given more treatment days. Leptin treated mice 
were expected to lose weight. While that result was not 
observed, leptin treated mice did have reduced food 
consumption relative to the vehicle treated mice, and they 
also did not gain weight over the course of the study, like 
the vehicle treated mice did.
Despite the prediction that the cross-sectional area 
of adipocytes would change with changes in body weight, 
omental and subcutaneous adipocyte area were not correlated 
with day seven weight change. This suggests that these two 
80
adipose sites may not be directly affected by acute 
fluctuations in body mass, but rather may have a role in 
long term energy balance with long term body mass 
fluctuations. Moreover, the duration of this study may have 
not been long enough to see significant effects.
The size of hepatic LD is indicative of whether the 
liver is undergoing lipid synthesis, disposal, or storage. 
Large lipid droplets (> 100 pm2) represent a storage form of 
lipids, whereas small lipid droplets (< 100 pm2) may suggest 
either lipid synthesis, lipid export, and/or p-oxidation. 
Understanding how the liver is handling lipids in response 
to the different treatments allows for a better 
understanding of the lipid trafficking that occurs during 
these different conditions. Small LDs were abundant in the 
leptin treated mice, suggesting leptin stimulates hepatic 
lipid breakdown by p-oxidation and/or lipid export. This is 
important because it leads to a reduction in fatty liver 
observed in ob/ob mice. Large LDs were abundant in the 
vehicle and IOP treated mice, but the livers of leptin/IOP 
treated mice had the most area covered by large LDs. It is 
not known whether starvation has a major impact on hepatic 
lipid trafficking; however, starvation does suppress 
hepatic fatty acid synthesis (Kornacker 1965) . The results 
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seen in the leptin/IOP treated mice could be due to leptin 
induced lipid breakdown, but due to the high hepatic lipid 
content in this group, the LDs that are broken down most 
likely cannot be exported or undergo |3-oxidation. This 
suggests that thyroid hormone may be required to work 
either in concert with leptin or independently to export 
lipids out of the liver or increase p-oxidation. 
Comparison to Previous Work in Dr. Fehn's Lab
Leptin/thyroid hormone interactions have been seen in 
previous studies on ob/ob mice (Fehn et al. 1999; Reno and 
Fehn 2007) . Ob/ob mice given exogenous leptin increased 
thyroid hormone concentration (Fehn et al. 1999). Moreover, 
leptin was previously shown to promote hepatic LD breakdown 
(Reno and Fehn 2007). Ob/ob mice given excess T3 (thyroid 
hormone) in addition to leptin reduced hepatic lipid 
content, whereas the absence of leptin in T3 treated mice 
resulted in hepatic steatosis. This suggests a possible 
interaction between leptin and thyroid hormone influencing 
lipid trafficking. Mice given IOP to reduce T3 concentration 
showed massive hepatic steatosis. In the present study, IOP 
treatment did show hepatic steatosis, but it was to the 
same extent as observed in the vehicle group.
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Fehn et al. (1999) found that omental and subcutaneous 
adipocytes were largest in leptin treated mice, and mice in 
all other treatment groups had similar adipocyte size. In 
the present study, leptin treated mice had the largest 
omental adipocytes, whereas leptin/IOP treated mice had the 
smallest areas. Vehicle, leptin, and IOP treated mice all 
had similar subcutaneous adipocytes while the adipocytes in 
the leptin/IOP group were smaller. This supports the idea 
that mice use subcutaneous lipid during starvation. There 
are no previous data on adipocyte area or hepatic lipid 
contents after leptin/IOP treatment.
The present studies confirm the ability of leptin to 
reduce hepatic lipid content and the body's ability to 
store lipid in the proper tissues (adipose). However, there 
is some kind of dysregulation in this process in the face 
of reduced thyroid hormone concentration. The interaction 
between leptin and T3 is poorly understood and needs further 
investigation.
IOP and leptin/IOP treated mice decreased mean daily 
food consumption in the present study compared to vehicle 
treated mice, whereas Underhill (2000) found a decrease in 
only the leptin and leptin/IOP treated mice. The IOP 
treated mice in the present study became sick in the first 
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couple of days of treatment. Therefore, the differences 
seen within this group between the present study and 
Underhill (2000) may be due to the mice not eating the 
first couple of days. In Underhill's study, mice receiving 
IOP did get sick, but there is no record of them not 
eating. Furthermore, in Underhill's study, food consumption 
was not reported mass specifically.
Relative changes in body mass were different between 
the two studies. While both the vehicle and leptin/IOP 
groups in both studies showed weight gain or weight loss, 
respectively, the leptin treated mice in the present study 
did not change in body mass while the same treatment group 
in Underhill's study did. Moreover, IOP treated mice in the 
present study lost weight while in Underhill's study those 
mice increased in body mass. In the present study, the 
sickness in the IOP treated mice may be the cause of the 
decreased food consumption as well as the decreased body 
mass. I predicted that the IOP treated mice should eat 
similar amounts of food relative to vehicle treated mice 
and should gain a similar amount of weight because low 
thyroid hormone concentration results in decreased 
lipolysis and p-oxidation.
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Oxygen consumption rates in Underhill's study were 
approximately 4 ml O2-min_1 for vehicle, leptin, and 
leptin/IOP treated mice. He did not report mass-specific 
V02. In the present study, all of the mice consumed about 
3.00 ± 0.16 ml 02-min“1 (0.03 ± 0.0016 ml 02-min_1 -g-1). 
Underhill's study showed all groups with an RQ of 0.7, 
indicating lipid metabolism. The RQ in the present study 
showed the leptin/IOP group had an RQ of 0.78, showing a 
tendency to utilize lipids in metabolism, but the other 
three groups had values of 0.86 ± 0.012, indicating both 
carbohydrate and lipid metabolism.
Underhill's treatments were done for nine days, 
whereas in the present study they were done for only seven 
days. This may account for some of the differences seen 
between these. However, Underhill also did not take body 
mass into account in his analyses, and mice became ill in 
the present study. Body weight can affect the analysis 
because the size of an animal will alter some of the 
parameters assessed. Taking all of these complicating 
factors into account, it is clear that metabolic parameters 
in the C57BL/6J ob/ob mice need to be reanalyzed for a 
better understanding of what leptin and reduced thyroid 
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hormone concentrations will do to lipid metabolism in the 
absence of starvation.
Conclusion and Future Study
Since the IOP treatment in a previous study (Reno and
Fehn 2007) resulted in massive hepatic steatosis, we 
wondered if IOP treatment combined with leptin would have 
the same effect on liver lipid content as leptin treatment 
alone. This hypothesis was not supported. The massive 
hepatic steatosis observed in leptin/IOP treated mice, and 
lack of steatosis in leptin treated mice, may indicate that 
leptin and thyroid hormone work together at one of the 
lipid export pathways. In addition, the hepatic LD content 
in leptin/IOP treated mice suggests that there is 
obstruction in lipid breakdown as well as export.
Therefore, there may be multiple pathways at which these 
two hormones work in concert. The hypothesis that leptin 
administered in combination with IOP will correct the lipid 
trafficking dysregulation (including reduce hepatic 
steatosis) observed in a lowered thyroid hormone 
environment was not supported. Due to the starvation that 
occurred in two of the groups, this study has not 
conclusively established a relationship between leptin and 
thyroid hormone in lipid trafficking in obese mice.
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However, the observations and comparisons made herein 
further support the possibility of such an interaction. 
Further studies to isolate proteins involved in the process 
of hepatic lipid breakdown and export may reveal what such 
an interaction might be. Experiments that look at the role 
of apoB and very low density lipoproteins (VLDLs) in 
packing lipids for export may help us understand if this 
postulated interaction is at the site of hepatic lipid 
export. In addition, markers that follow 0-oxidation may 
elucidate if decreased lipid metabolism in the hepatocytes 
is the cause of the observed steatosis. A better 
understanding of these processes may provide possible 
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The vehicle solution was prepared with 20 mN Tris/HCl, 
pH 8.0. Five mice received a daily dose of 3 pl/g Mb 
vehicle. Leptin (R and D3 systems, #498-OB) was dissolved 
in 20 mM Tris/HCl, pH 8.0, as directed by the manufacturer. 
Five mice received a daily dose of 3 pg/g Mb of leptin (3 
pl/g Mb of 1 pg/pl). Iopanoic acid (Methimazole, Western 
Medical Supply) was prepared under a fume hood by pondering 
tablets with a mortar and pestle while the tablets were 
still in foil. The powder was transferred to a vial, mixed 
with 0.1 M NaOH, and sonicated to dissolve, giving a 
concentration of 15 pg/pl. This solution was combined with 
0.1 M HC1 and resonicated. The pH was brought to about 7.8 
with 0.1 M HC1. The solution was sonicated again and 
diluted with distilled water. Five mice received a daily 
dose of 50 pg/g Mb IOP (3.33 pl/g Mb of 15 pg/pl). All of 
the above doses were chosen based on success with previous 
experimentation with the same dosages in ob/ob mice (Fehn 
et al. 1999; Reno and Fehn 2007).
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The leptin and saline solutions were made, aliquoted,
and stored at -20 °C until use. The IOP was made fresh 






The liver pieces were placed in a 2.5% 
glutaraldehyde/Tyrode's Cacodylic acid solution for primary 
fixation overnight. The next day, the tissues were washed 
twice with cacodylic acid buffer (ph 7.4), incubated for 
one hour and overnight, respectively. On day 3, the tissues 
were incubated with fresh cacodylic acid buffer for 30 
minutes. They then were allowed to post-fix with 2% osmium 
tetroxide (OSO4) for about two hours. The tissues were 
incubated with cacodylic acid buffer for one hour, followed 
by a dehydration series starting at 50% ethanol and going 
through to 100% dry ethanol. Each dehydration step required 
45 min to 2 hours, with the higher concentrated alcohols 
requiring the longer incubation times. The 100% dry ethanol 
was replaced with 100% propylene oxide for 2 hours. This 
solution was then replaced with a 1:2 epon:propylene oxide 
mixture and allowed to incubate overnight on a rotator. On 
day 4, the 1:2 epon:propylene oxide solution was replaced 
with 1:1 epon:polypropylene oxide and allowed to incubate 
for 2 hours while rotating. This solution was replaced with 
100% epon and allowed to penetrate into the tissues 
overnight while on a rotator. All the above mentioned steps 
were done at room temperature. On day 5, the tissues and
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epon were placed into embedding capsules and allowed to 
polymerize for approximately 18 hours at 60° C.
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